Nautilus Biotechnology Analyst Ratings
Nautilus Biotechnology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/03/2023 | 94.81% | Morgan Stanley | $6 → $6 | Reiterates | Equal-Weight → Equal-Weight |
| 08/03/2022 | 94.81% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 08/03/2022 | -35.06% | Goldman Sachs | $4 → $2 | Maintains | Neutral |
| 07/14/2022 | 29.87% | Goldman Sachs | $5 → $4 | Maintains | Neutral |
| 04/13/2022 | 62.34% | Goldman Sachs | $9 → $5 | Maintains | Neutral |
| 01/06/2022 | 159.74% | Morgan Stanley | → $8 | Initiates Coverage On | → Equal-Weight |
| 11/02/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/04/2021 | 224.68% | Goldman Sachs | → $10 | Initiates Coverage On | → Neutral |
| 07/13/2021 | 322.08% | Jefferies | → $13 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/03/2023 | 94.81% | 摩根士丹利 | 6 美元 → 6 美元 | 重申 | 等重 → 等重 |
| 08/03/2022 | 94.81% | 摩根士丹利 | 8 美元 → 6 美元 | 維護 | 重量相等 |
| 08/03/2022 | -35.06% | 高盛 | 4 美元 → 2 美元 | 維護 | 中立 |
| 07/14/2022 | 29.87% | 高盛 | 5 美元 → 4 美元 | 維護 | 中立 |
| 2022 年 4 月 13 日 | 62.34% | 高盛 | 9 美元 → 5 美元 | 維護 | 中立 |
| 01/06/2022 | 159.74% | 摩根士丹利 | → 8 美元 | 啓動覆蓋開啓 | → 重量相等 |
| 11/02/2021 | — | Cowen & Co. | 啓動覆蓋開啓 | → 跑贏大盤 | |
| 08/04/2021 | 224.68% | 高盛 | → 10 美元 | 啓動覆蓋開啓 | → 中立 |
| 2021 年 7 月 13 日 | 322.08% | 傑富瑞 | → 13 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Nautilus Biotechnology (NAUT)?
鸚鵡螺生物技術（NAUT）的目標價格是多少？
The latest price target for Nautilus Biotechnology (NASDAQ: NAUT) was reported by Morgan Stanley on August 3, 2023. The analyst firm set a price target for $6.00 expecting NAUT to rise to within 12 months (a possible 94.81% upside). 1 analyst firms have reported ratings in the last year.
摩根士丹利於2023年8月3日公佈了鸚鵡螺生物技術（納斯達克股票代碼：NAUT）的最新目標股價。這家分析公司將目標股價定爲6.00美元，預計NAUT將在12個月內升至12個月內（可能上漲94.81％）。去年有1家分析公司公佈了評級。
What is the most recent analyst rating for Nautilus Biotechnology (NAUT)?
分析師對鸚鵡螺生物技術（NAUT）的最新評級是多少？
The latest analyst rating for Nautilus Biotechnology (NASDAQ: NAUT) was provided by Morgan Stanley, and Nautilus Biotechnology reiterated their equal-weight rating.
Nautilus Biotelus Biotechnology（納斯達克股票代碼：NAUT）的最新分析師評級由摩根士丹利提供，鸚鵡螺生物技術重申了其同等權重評級。
When is the next analyst rating going to be posted or updated for Nautilus Biotechnology (NAUT)?
Nautilus Biotelus Biotechnology（NAUT）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nautilus Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nautilus Biotechnology was filed on August 3, 2023 so you should expect the next rating to be made available sometime around August 3, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Nautilus Biotelus Biotechnology的高管和客戶交談，以及聽取業績電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Nautilus Biotelus Biotechnology的最後一次評級是在2023年8月3日提交的，因此您應該預計下一個評級將在2024年8月3日左右公佈。
Is the Analyst Rating Nautilus Biotechnology (NAUT) correct?
分析師對鸚鵡螺生物技術（NAUT）的評級是否正確？
While ratings are subjective and will change, the latest Nautilus Biotechnology (NAUT) rating was a reiterated with a price target of $6.00 to $6.00. The current price Nautilus Biotechnology (NAUT) is trading at is $3.08, which is out of the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Nautilus Biotechnology（NAUT）的評級得到了重申，目標股價爲6.00美元至6.00美元。Nautilus Biotelus Biotechnology（NAUT）目前的交易價格爲3.08美元，超出了分析師的預測區間。